This study sought to evaluate acute toxicity and local control in patients who underwent extracranial stereotactic body radiation therapy (SBRT) for paracardiac and cardiac metastatic lesions, defined as such when located at a maximum distance of 1 cm from the heart or inside its parenchyma. Between January 2009 and May 2011, 16 patients with paracardiac and cardiac lesions were treated with SBRT. For dose specification, in 15 of 16 patients, the prescription dosage was 36 Gy in three fractions (70% isodose). In one patient, the target lesion was inside the heart, and the prescription dosage was 30 Gy in three fractions (70% isodose). Regarding response to stereotactic radiotherapy, we recorded one (6%) complete response (CR), six (37%) partial responses (PR), five (32%) stable disease (SD) and four (25%) local failures. Median interval to local failure was 5.2 (range, 3-12) months. The cause of death was distant progression of disease in all four patients. Compliance to treatment was excellent; no patient developed cardiological symptoms or electrocardiographic abnormalities, even months after SBRT. Results of our retrospective study indicate that SBRT represents a safe and effective treatment option for patients with cardiac and paracardiac metastases.

Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience / Bonomo P;Livi L;Rampini A;Meattini I;Agresti B;Simontacchi G;Paiar F;Mangoni M;Bonucci I;Greto D;Masi L;Doro R;Marrazzo L;Biti G. - In: LA RADIOLOGIA MEDICA. - ISSN 0033-8362. - STAMPA. - 118:(2013), pp. 1055-1065. [10.1007/s11547-013-0932-0]

Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.

LIVI, LORENZO;MEATTINI, ICRO;PAIAR, FABIOLA;MANGONI, MONICA;MARRAZZO, LIVIA;BITI, GIAMPAOLO
2013

Abstract

This study sought to evaluate acute toxicity and local control in patients who underwent extracranial stereotactic body radiation therapy (SBRT) for paracardiac and cardiac metastatic lesions, defined as such when located at a maximum distance of 1 cm from the heart or inside its parenchyma. Between January 2009 and May 2011, 16 patients with paracardiac and cardiac lesions were treated with SBRT. For dose specification, in 15 of 16 patients, the prescription dosage was 36 Gy in three fractions (70% isodose). In one patient, the target lesion was inside the heart, and the prescription dosage was 30 Gy in three fractions (70% isodose). Regarding response to stereotactic radiotherapy, we recorded one (6%) complete response (CR), six (37%) partial responses (PR), five (32%) stable disease (SD) and four (25%) local failures. Median interval to local failure was 5.2 (range, 3-12) months. The cause of death was distant progression of disease in all four patients. Compliance to treatment was excellent; no patient developed cardiological symptoms or electrocardiographic abnormalities, even months after SBRT. Results of our retrospective study indicate that SBRT represents a safe and effective treatment option for patients with cardiac and paracardiac metastases.
2013
118
1055
1065
Bonomo P;Livi L;Rampini A;Meattini I;Agresti B;Simontacchi G;Paiar F;Mangoni M;Bonucci I;Greto D;Masi L;Doro R;Marrazzo L;Biti G
File in questo prodotto:
File Dimensione Formato  
Bonomo et al Rad Med 2013.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 174.09 kB
Formato Adobe PDF
174.09 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/819917
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact